sb 202190 has been researched along with Rheumatoid Arthritis in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farag, AK | 1 |
| Elkamhawy, A | 1 |
| Londhe, AM | 1 |
| Lee, KT | 1 |
| Pae, AN | 1 |
| Roh, EJ | 1 |
1 other study available for sb 202190 and Rheumatoid Arthritis
| Article | Year |
|---|---|
Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cell Survival; Dose-Respons | 2017 |